Privacy voorkeur

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ASH 2012 | Hematology News Program 3

Third Hematology TV News Program from the ASH 2012

  • TPA-agonist romiplostim: can we reconsider its use in MDS?
  • Have we arrived into the era of targeted therapy in CLL with ibrutinib?
  • JAK-inhibition may be relevant for MPN beyond myelofibrosis
  • This program is editorially independent and is financially made possible by

Related items

Congress news

EHA 2012 | News Program 16/06/12

EHA 2012 Hematology TV News Program June 16 Myelodysplastic Syndromes Interview Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma

Congress news

EHA 2012 | News Program June 16

EHA 2012 Hematology TV News Program June 16. Myelodysplastic Syndromes Interview Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma

Congress news

ASH 2014 Highlight 3 - Leukemia

Highlight on leukemia: Prof. Dr. med. Uwe Platzbecker tells if ATRA+arsenicumtrioxide should become the new standard care for non-high risk APML by illustrating the Italian-German APL0406 trial. Ian Flinn MD PhD provides an overview on novel therapies for CLL. Prof. Dr. Michele Baccarani discusses whether imatinib remains the standard therapy for CML by elaborating on the DASISION, SPIRIT-2 and EPIC trails. Prof. Dr. Rien van Oers concludes with the PROLONG trial which investigates ofatumumab maintenance therapy in R/R CLL.

Congress news

ASH 2011 | Hematology Journal 3

Host Geoff Watts discusses exciting research into gene mutations associated with MDS as well as therapeutic progress with Professor Norbert Gattermann. Topics are a.o. spliceosome gene mutations, the issues around the treatment of MDS with lenalidomide and the debate on data of iron chelation therapy in MDS patients.

Congress news

EHA 2014 - News Report 1

EHA 2014 – News Report 1 on: CLL by Prof. Stephan Stilgenbauer, the José Carreras Lecture ‘Genetics to guide management of patients with AML by Prof. Hartmut Döhner, the pathophysiology of auto-immune hemolytic anemia by Prof. Hannah Tamary and Stem Cell Transplantation: focus on chronic GvHD by Prof William Arcese.

Congress news

ASH 2014 Highlight 2 - Lymphoma

Highlight on lymphoma: First, Fredrick Hagemeister MD PhD discusses the usage of PD-1 targeted therapy in Hodgkin and Non-Hodgkin lymphoma. Christiane Pott MD PhD then illustrates the importance of minimal residual disease eradication in mantle cell lymphoma. Thereafter, Luca Biasco PhD and Serena Scala MSc explain how engineered T-cells can be employed to treat B-cell lymphomas. Finally, Jia Ruan MD PhD talks about new treatments for mantle cell lymphoma and specifically a chemotherapy-free regimen with the biologic doublet lenalidomide and rituximab.